Difficulty: Medium
Average Score: 95%
Practice
Which of the following medications is given concurrently with coronary angioplasty or intervention?
Correct answer
A
Rationale
In the context of pharmacology and lifespan considerations, the correct answer is A) Bivalirudin; Aspirin.
Bivalirudin is a direct thrombin inhibitor often used during coronary angioplasty or intervention to prevent blood clot formation. Aspirin, on the other hand, is an antiplatelet medication that helps reduce the risk of clotting by inhibiting platelet aggregation. When used together, these medications provide a dual mechanism of action to prevent clot formation during and after the procedure, reducing the risk of complications such as stent thrombosis.
Option B) Fondaparinux; Heparin is incorrect because while both are anticoagulants, they are not typically used together during coronary interventions due to an increased risk of bleeding complications.
Option C) Enoxaparin; Coumarins is also incorrect because coumarins (such as warfarin) are vitamin K antagonists that are not typically used acutely during coronary interventions. Enoxaparin, a low molecular weight heparin, may be used in some cases but is not the standard combination.
Option D) Vitamin K inhibitors; Xa is incorrect because vitamin K inhibitors (like warfarin) are not typically used acutely during coronary interventions. Xa inhibitors, such as rivaroxaban, are also not commonly used in this setting.
In an educational context, understanding the rationale behind the choice of medications during coronary interventions is crucial for healthcare providers involved in the care of patients undergoing these procedures. Knowledge of the appropriate pharmacological agents, their mechanisms of action, and potential interactions is essential for providing safe and effective patient care in such critical settings.
Bivalirudin is a direct thrombin inhibitor often used during coronary angioplasty or intervention to prevent blood clot formation. Aspirin, on the other hand, is an antiplatelet medication that helps reduce the risk of clotting by inhibiting platelet aggregation. When used together, these medications provide a dual mechanism of action to prevent clot formation during and after the procedure, reducing the risk of complications such as stent thrombosis.
Option B) Fondaparinux; Heparin is incorrect because while both are anticoagulants, they are not typically used together during coronary interventions due to an increased risk of bleeding complications.
Option C) Enoxaparin; Coumarins is also incorrect because coumarins (such as warfarin) are vitamin K antagonists that are not typically used acutely during coronary interventions. Enoxaparin, a low molecular weight heparin, may be used in some cases but is not the standard combination.
Option D) Vitamin K inhibitors; Xa is incorrect because vitamin K inhibitors (like warfarin) are not typically used acutely during coronary interventions. Xa inhibitors, such as rivaroxaban, are also not commonly used in this setting.
In an educational context, understanding the rationale behind the choice of medications during coronary interventions is crucial for healthcare providers involved in the care of patients undergoing these procedures. Knowledge of the appropriate pharmacological agents, their mechanisms of action, and potential interactions is essential for providing safe and effective patient care in such critical settings.